Print

Special sessions

 

Monday, May 2, 5:30-7pm MT

ARVO Imaging 2022 Special Session
Organizers: Joel S. Schuman, James G. Fujimoto, Wolfgang Drexler
Speakers: Bruce Berkowitz, Kate Grieve, Yali Jia, Donald Miller and Siamak Yousefi

The ARVO Imaging 2022 Special Session presents cutting edge advances in ocular imaging. Since the ARVO Imaging conference was not held this year due to the coronavirus pandemic, this 90-minute special session provides a highly curated selection of presentations representing an array of imaging technologies and topics by leaders in the field. Topics include visualization of retinal cellular structure using adaptive optics (AO) optical coherence tomography (OCT), full field OCT, high-speed handheld OCT and OCT angiography (OCTA), artificial intelligence for OCT in glaucoma and MRI biomarkers of sight threatening diseases.

Tuesday, May 3, 8-10am MT

NEI Update and Regenerative Medicine: Cell Sources and Characterization
Speakers: Michael Chiang, Tom Greenwell, Tenneille Ludwig, Sally Temple, Dennis Clegg, Tim Blenkinsop, Budd Tucker, Marianna Madrid and Kapil Bharti

Research advancements in cellular therapies for degenerative eye diseases suggest we are closer to the goal of reaching the clinic.  This session will highlight six topics that are important aspects of cell sources and characterization of pluripotent and endogenous stem cells. It will inform the community about scientific and regulatory considerations that are important when working on stem cell-based therapies and how to get them to clinic. As part of the NEI Audacious Goals Initiative, getting photoreceptor and retinal ganglion cell replacements to the clinic are important future goals.

Tuesday, May 3, 6-7:30pm MT

Update from the DRCR Retina Network
Speakers: Daniel Martin, Paolo Silva, Dennis Marcus, Carl Baker, Judy Kim and Jennifer Sun

This session will present clinically relevant and timely results from DRCR Retina Network clinical studies. Topics include the 4-year results of an observational study evaluating the risk of diabetic retinopathy worsening among eyes with non-proliferative diabetic retinopathy with and without predominately peripheral lesions on ultra-widefield photographs; primary results from a randomized controlled trial of Photobiomodulation therapy for center-involved diabetic macular edema; a comparison of clinical visual acuity versus ETDRS visual acuity, and an evaluation of the response to anti-VEGF treatment for center-involved DME across several Network trials.